Sold as Didronel. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 16, 2026, FDA lists 3 applications for Etidronate Disodium (sold as Didronel), first approved Sep 1, 1977, with 2 new uses approved and 0 published complete response letters.
| Effect of Different Irrigation Protocols on Postoperative Endodontic Pain and InflammationIrrigation Solution, Postoperative Pain · Suez Canal University | Not applicable | Active, not recruiting | Aug 11, 2025 |
| The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma ElasticumPseudoxanthoma Elasticum · UMC Utrecht | Phase 3 | Recruiting | Apr 27, 2023 |
| Treatment of Ectopic Calcification in Fahr's Disease or SyndromeFahr Disease, Fahr Syndrome · UMC Utrecht | Phase 2 | Recruiting | Dec 22, 2022 |
| Sep 1, 1977 | DidronelNDA 17831 · New molecular entity | Apil | 41 | Discontinued |
| Apr 20, 1987 | DidronelNDA 19545 · New dosage form | Mgi Pharma Inc | 6 | Discontinued |
| Jan 24, 2003 | Etidronate DisodiumANDA 75800 | Pharmobedient | 5 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA